PHAP1 promotes glioma cell proliferation by regulating the Akt/p27/stathmin pathway
Open Access
- 18 April 2018
- journal article
- research article
- Published by Wiley in Journal of Cellular and Molecular Medicine
- Vol. 22 (7) , 3595-3604
Abstract
PHAP1 (Putative HLA‐DR‐associated protein 1), also termed acidic leucine‐rich nuclear phosphoprotein 32A (ANP32A), Phosphoprotein 32 (pp32) or protein phosphatase 2A inhibitor (I1PP2A), is a multifunctional protein aberrantly expressed in multiple types of human cancers. However, its expression pattern and clinical relevance in human glioma remain unknown. In this study, Western blotting and immunohistochemistry analysis demonstrated PHAP1 protein was highly expressed in glioma patients, especially in those with high‐grade disease. Publicly available data also revealed high levels of PHAP1 were associated with poor prognosis in glioma patients. The functional studies showed that knock‐down of PHAP1 suppressed the proliferation of glioma cells, while overexpression of PHAP1 facilitated it. The iTRAQ proteomic analysis suggested that stathmin might be a potential downstream target of PHAP1. Consistently, PHAP1 knock‐down significantly decreased the expression of stathmin, while overexpression of PHAP1 increased it. Also, the upstream negative regulator, p27, expression levels increased upon PHAP1 knock‐down and decreased when PHAP1 was overexpressed. As a result, the phosphorylated Akt (S473), an upstream regulator of p27, expression levels decreased upon silencing of PHAP1, but elevated after PHAP1 overexpression. Importantly, we demonstrate the p27 down‐regulation, stathmin up‐regulation and cell proliferation acceleration induced by PHAP1 overexpression were dependent on Akt activation. In conclusion, the above results suggest that PHAP1 expression is elevated in glioma patients, which may accelerate the proliferation of glioma cells by regulating the Akt/p27/stathmin pathway.Keywords
Funding Information
- National Natural Science Foundation of China (81402069, 81472345, 81672490)
- Natural Science Foundation of Jiangsu Province (BK20151165)
- China Postdoctoral Science Foundation (2014M551662, 2016T90507)
This publication has 43 references indexed in Scilit:
- Stathmin: a protein with many tasks. New biomarker and potential target in cancerExpert Opinion on Therapeutic Targets, 2011
- pp32, an INHAT component, is a transcription machinery recruiter for maximal induction of IFN-stimulated genesJournal of Cell Science, 2011
- pp32 (ANP32A) Expression Inhibits Pancreatic Cancer Cell Growth and Induces Gemcitabine Resistance by Disrupting HuR Binding to mRNAsPLOS ONE, 2010
- EBV‐encoded LMP1 regulates Op18/stathmin signaling pathway by cdc2 mediation in nasopharyngeal carcinoma cellsInternational Journal of Cancer, 2008
- Nitrosoureas Inhibit the Stathmin-Mediated Migration and Invasion of Malignant Glioma CellsCancer Research, 2008
- pp32/PHAPI determines the apoptosis response of non-small-cell lung cancerCell Death & Differentiation, 2007
- Increased expression and differential phosphorylation of stathmin may promote prostate cancer progressionThe Prostate, 2007
- Adenovirus E4orf6 targets pp32/LANP to control the fate of ARE-containing mRNAs by perturbing the CRM1-dependent mechanismJournal of Cell Biology, 2005
- The role of stathmin in the regulation of the cell cycleJournal of Cellular Biochemistry, 2004
- Conserved microtubule–actin interactions in cell movement and morphogenesisNature Cell Biology, 2003